AI boom raises due diligence risks, Theranos whistleblower warns

Traders Union
All News
Business & Wealth
AI boom due diligence risks

Highlights

Theranos whistleblower Tyler Shultz warns that current AI investment cycles resemble Theranos' $10 billion valuation built without functioning technology.
Shultz highlights verification challenges in AI, citing difficulties distinguishing original innovations from products merely wrapping existing tools like ChatGPT.
Wealthy individuals backed Theranos as it withheld scientific evidence, and Shultz cautions similar due diligence gaps may persist amid the AI sector's investment frenzy.

Shultz draws parallels with Theranos fundraising

As reported by TechCrunch, citing The San Francisco Standard, Shultz says the current AI investment cycle revives concerns exposed by Theranos, the blood-testing startup that reached a valuation of about $10 billion even though its technology never functioned as promised.

Shultz, whose first job after college was at Theranos, helped expose the company’s inaccurate blood-testing devices after they were used in Walgreens stores and produced faulty results for patients. He says investors should move beyond informal backing decisions, arguing that the era of brief meetings followed by large checks should be over.

He also says Holmes effectively turned that investor behavior into an extreme case, calling Theranos the biggest angel funding round of all time. His grandfather, former U.S. Secretary of State and Treasury Secretary George Shultz, was among the company’s notable investors and board members.

AI sector faces scrutiny over verification challenges

Shultz says AI presents a particular due diligence problem because it can be difficult to distinguish truly original technology from products built as simple wrappers around existing tools such as ChatGPT. In his view, that makes the sector especially vulnerable to founders who want to mislead investors while capital remains abundant.

Theranos raised much of its funding from wealthy individual investors, including the DeVos and Walton families, rather than traditional venture capital firms. The company withheld scientific evidence from prospective backers, citing trade secret concerns, a stance that discouraged many leading Silicon Valley venture firms.

Shultz says he remains uneasy that the lessons from the Theranos collapse could fade during the AI boom. He also says Elizabeth Holmes appears to be preparing a second act, adding to his concern about what may come next.

In our earlier article on the rapid buildout of U.S. AI data centers, we highlighted how soaring costs, construction delays, and power constraints are starting to test investor confidence. We noted that only a portion of planned projects appear credible and that financing pressures—alongside grid limits and local opposition—could make it harder for developers to deliver on ambitious expansion promises.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.